Roche, Affitech Ink Development Deal For Oncology-Targeted Monoclonal Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche intends to commercialize cancer antibodies developed using Affitech’s phagemid technology, firms say.